StoneX Group’s Allogene Therapeutics ALLO Stock Holding History

StoneX Group’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,867	Closed	-$20.4K	–	927
2025 Q4	$20.4K	Buy	+14,867	New	+$19.6K	﹤0.01%	971

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

StoneX Group's ALLO Position: Q1 2026 in Review

StoneX Group sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 14,867 shares — an estimated $20.4K sold.

StoneX Group first reported a position in ALLO in Q4 2025 and held it in 1 quarter. The position peaked at $20.4K in Q4 2025. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

StoneX Group reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 14,867 Allogene Therapeutics shares in Q1 2026, an estimated $20.4K.
StoneX Group first reported a position in Allogene Therapeutics in Q4 2025 and held it in 1 quarter.
StoneX Group's Allogene Therapeutics position peaked at $20.4K in Q4 2025.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.